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Abstract 
Background: The tumor cells were needed to rearrange the extracellular matrix (ECM) and reorganize their cytoskel-
eton to facilitate the cell motility during the tumor invasion. The proinflammatory cytokine interleukin-17A (IL-17A) is 
reported to up-regulate tumor invasiveness via ECM degradation by matrix metalloproteinases (MMPs). However the 
precise effects of IL-17A-dependent invasion remain to be characterized. The aim of this study was to elucidate the 
mechanisms underlying IL-17A-induced MMP-3 expression in the human synovial sarcoma cells HS-SY-II.
Methods: HS-SY-II cells were incubated with IL-17A. In some experiments, the cells were pre-incubated with an 
anti-IL-17 receptor polyclonal antibody (IL-17R Ab) or inhibitors for signaling cascade prior to addition of IL-17A. The 
expression of MMP-3 was determined by real-time reverse-transcription polymerase chain reaction (RT-PCR) and 
western blotting. IL-17R expression in HS-SY-II cells was assessed by immunofluorescence microscopy, while the phos-
phorylation of signaling molecules was measured by western blotting.
Results: IL-17A increased MMP-3 mRNA and protein expression. HS-SY-II cells express the IL-17R on their surface and 
blockage of IL-17A-IL-17R binding by IL-17R Ab suppressed IL-17A-mediated induction of MMP-3. IL-17A induced the 
phosphorylation of three components of the mitogen-activated protein kinase (MAPK) pathway including extracel-
lular signal-regulated kinase 1/2 (ERK1/2), p38 MAPK, and c-Jun NH2-terminal kinase (JNK). Pre-treatment of the cells 
with inhibitors of ERK1/2, p38 MAPK, and JNK attenuated the IL-17A-induced phosphorylation of activator protein-1 
(AP-1) subunits and the expression of MMP-3 mRNA.
Conclusion: Our results indicate an essential role for MAPKs in the induction of MMP-3 in synovial sarcoma cells, 
through AP-1 activation.
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Background
Synovial sarcoma is a clinically aggressive malignant soft 
tissue tumor and the 5- and 10-year survival rates have 
been reported as low as 36 and 20  %, respectively [1]. 
Furthermore, synovial sarcomas have a high rate of local 
recurrence and metastasis [2]. Therefore, establishment 
of efficient therapeutic strategies are required to improve 
the prognosis of synovial sarcoma. Inflammation is a key 
regulatory process during tumor development. Con-
tinuous exposure to inflammatory cytokines is known 
to cause tumorigenesis [3]. Thus, these cytokines are 
of interest as therapeutic targets to prevent tumor 
progression.
Pro-inflammatory cytokine interleukin-17A (IL-17A) is 
a major member of IL-17 family and is secreted mainly 
by Th17 cells [4]. The elevated expression of IL-17A has 
been implicated in the pathogenesis of a wide range of 
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inflammatory, infectious, and autoimmune diseases [5]. 
In addition, accumulating data showed that the role of 
IL-17A in cancer initiation, growth, and metastasis was 
crucial [6–8].
Matrix metalloproteinases (MMPs) degrade a wide 
range of substrates, including extracellular matrix (ECM) 
components [9], and numerous studies demonstrated that 
elevated levels of MMPs are associated with tumor growth, 
cancer progression, metastasis, and shortened survival in 
patients [10, 11]. MMP-3 has been recognized as one of 
the major proteases responsible for ECM turnover and 
cell–cell interactions, as well as tumor metastasis [12, 13].
The IL-17 family signals via their correspondent recep-
tors activate downstream pathways, including mitogen-
activated protein kinases (MAPKs). The MAPK signal 
transduction pathway, comprising extracellular signal-
regulated kinase 1/2 (ERK1/2), p38 MAPK, and c-Jun 
NH2-terminal kinase (JNK), controls gene expression, via 
the phosphorylation and regulation of transcription fac-
tors, co-regulatory proteins, and chromatin.
Previous studies showed that IL-17A induces MMP-1 
and MMP-9 via ERK1/2 and p38 MAPK-dependent 
activation of the transcriptional factors activator pro-
tein-1 (AP-1) and nuclear factor-kappa B (NF-κB) [14, 
15]. Although both IL-17A and MMP-3 are known to be 
involved in the initiation and progression of tumor cells, 
their interaction has yet to be determined. In the present 
study, we examined the molecular mechanism by which 
IL-17A-induced MMP-3 expression in synovial sarcoma 
cells and demonstrated that IL-17 could regulate the 
expression of MMP-3 through MAPKs-AP-1 activation.
Methods
Reagents
Recombinant human IL-17A and anti-JNK monoclo-
nal antibody were purchased from R&D systems (Min-
neapolis, MN, USA). Anti-phospho-ERK monoclonal, 
anti-phospho-p38 MAPK monoclonal, anti-phospho-
JNK polyclonal, anti-phospho-c-Jun monoclonal, anti-
phospho-c-Fos monoclonal, anti-ERK monoclonal, 
anti-p38 MAPK monoclonal, anti-JNK polyclonal, anti-
c-Jun monoclonal, and anti-c-Fos monoclonal antibodies 
were purchased from Cell Signaling Technology (Beverly, 
MA, USA). Anti-phospho-IκB-α monoclonal, and anti-
IκB-α polyclonal antibodies were purchased from Santa 
Cruz Biotechnology (Dallas, TX, USA). Anti-MMP-3 
polyclonal antibody was purchased from Abcam (Tokyo, 
Japan). Anti-β-actin monoclonal antibody was obtained 
from Sigma (St. Louis, MO, USA).
Cell culture
HS-SY-II human synovial sarcoma cells were pur-
chased from Riken BRC (Ibaraki, Japan). The cells were 
maintained in Dulbecco’s Modified Eagle Medium 
(DMEM) supplemented with 10  % fetal bovine serum 
(FBS), 100 units/ml penicillin G potassium salt, and 
140 μg/ml streptomycin sulfate at 37 °C in an atmosphere 
of 5 % CO2.
Quantitative real‑time reverse transcription polymerase 
chain reaction (real time RT‑PCR)
Total RNA from HS-SY-II cells were extracted using an 
RNeasy Mini Kit (Qiagen, Valencia, CA, USA) accord-
ing to the manufacturer’s instructions. The RNA was 
transcribed with ReverTra Ace® quantitative PCR RT 
Master Mix (Toyobo, Life Science Department, Osaka, 
Japan) and amplified using a Mastercycler gradient 
(Eppendorf, Hamburg, Germany). PCR products were 
detected using FAST SYBR Green Master Mix (Applied 
Biosystems, Foster City, CA, USA) with the follow-
ing primer sequences: GAPDH, forward 5′-ATG GAA 
ATC CCA TCA CCA TCT T and reverse 5′-CGC CCC 
ACT TGA TTT TGG; MMP-3, forward 5′-TCG TTG 
CTG CTC ATG AAA TTG and reverse 5′-AGC TTC 
AGT GTT GGC TGA GTG A. Thermal cycling and 
fluorescence detection were performed using a StepOne 
Real-Time PCR System (Applied Biosystems). Rela-
tive changes in gene expression were calculated using 
the comparative CT method. Total cDNA abundance 
between samples was normalized using primers specific 
to the GAPDH gene.
Western blotting analysis
Total protein was extracted from the cells using sodium 
dodecyl sulfate (SDS) lysis buffer (75  mM Tris–HCl 
containing 2 % SDS and 10 % glycerol, pH 6.8) and pro-
tein contents were measured using a DC protein assay 
kit (Bio-Rad, Hercules, CA, USA). Equivalent amounts 
(30  μg) of total protein were electrophoresed using 
e-PAGEL (Atto, Tokyo, Japan), then transferred to poly-
vinylidene difluoride membranes (Merck Millipore, 
Billerica, MA, USA). Non-specific binding sites were 
blocked by immersing the membrane in Blocking one 
(Nakarai Tesque, Kyoto, Japan) for 1 h at room temper-
ature after which the membranes were treated with the 
diluted primary antibodies overnight at 4 °C, followed by 
horseradish-peroxidase-conjugated secondary antibod-
ies (GE Healthcare, Little Chalfont, UK) for 1 h at room 
temperature. After washing the membranes, chemilumi-
nescence was produced using the ECL western blotting 
detection reagent or the ECL Prime western blotting 
detection reagent (both from GE Healthcare UK, Buck-
inghamshire, UK). Band densities were determined using 
ChemiDoc™® XRS Plus molecular imager system (Bio-
Rad Laboratories). The blots were quantified by meas-
uring the relative band intensity normalized to changes 
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in the β-actin intensity using Image Lab™®2.0 software 
(Bio-Rad Laboratories).
MMP‑3 expression in HS‑SY‑II cells stimulated with IL‑17A
HS-SY-II cells were incubated with IL-17A (10  ng/ml) 
for 0-24  h. The mRNA level of MMP-3 was measured 
by real-time RT-PCR. To determine the expression of 
MMP-3 protein, whole-cell lysates were subjected to 
SDS-PAGE and western blot analysis, with the blots 
probed for MMP-3. Equivalent protein aliquots of cell 
lysates were also analyzed for β-actin.
Immunofluorescence microscopy for IL‑17R
HS-SY-II cells were cultured in 4-well Lab-Tek™® par-
manox chamber slides (Nagle Nunc International, 
Rochester, NY, USA) at a density of 1 ×  104 cells/well. 
The cells were fixed with 4  % paraformaldehyde for 
30  min at 4  °C, and quenched with 0.2  M glycine in 
phosphate-buffered saline (PBS, pH7.2). Specific bind-
ing sites were blocked with 1 % bovine serum albumin 
in PBS for 30 min at room temperature. The cells were 
then treated overnight at 4  °C with rabbit polyclonal 
anti-IL-17R (1:100; Santa Cruz Biotechnology), washed 
three times with PBS, and treated with Alexa Flour® 
488 conjugated goat anti-rabbit IgG (1:100; Molecular 
Probe, Invitrogen, Carlsbad, CA, USA) for 1 h at room 
temperature. After washing in PBS, the cells were incu-
bated with Alexa Fluor® 568 Phalloidin (1:150; Molecu-
lar Probe, Invitrogen) for 15 min at room temperature, 
followed by the addition of the nuclear staining agent 4′, 
6-diamino-2-phenylidole (DAPI). The cells were visu-
alized using a BZ-9000 fluorescence microscope (Key-
ence, Osaka, Japan). Images were captured digitally in 
real time and processed using the BZ-II imaging soft-
ware (Keyence).
Effect of IL‑17R neutralizing antibody on IL‑17A‑induced 
MMP‑3 expression in HS‑SY‑II cells
HS-SY-II cells were pre-treated with neutralizing anti-
body against IL-17R (IL-17R Ab; 0.5-5 μM; Cell Signaling 
Technology) for 1 h, then incubated with or without IL-
17A (10 ng/ml) for 12 h. The mRNA level of MMP-3 was 
measured by real-time RT-PCR.
MAPKs phosphorylation in HS‑SY‑II cells stimulated 
with IL‑17A
HS-SY-II cells were stimulated with IL-17A (10  ng/
ml) for 0–300  min. Whole-cell lysates were subjected 
to SDS-PAGE and western blot analysis, with the blots 
probed for phosphorylated ERK1/2, p38 MAPK, and 
JNK. Following visualization, the blots were stripped 
and re-probed for ERK1/2, p38 MAPK, and JNK. 
Equivalent protein aliquots of cell lysates were also ana-
lyzed for β-actin.
Effect of MAPKs inhibitors on IL‑17A‑induced MMP‑3 
expression in HS‑SY‑II cells
HS-SY-II cells were pretreated or not with inhibitors of 
ERK1/2 (U0126, 10  μM; Calbiochem, Darmstadt, Ger-
many), p38 MAPK (SB239063, 10  μM; Calbiochem), 
and JNK (SP600125, 10  μM; Calbiochem) for 1  h, fol-
lowed by incubation with 10  ng/ml IL-17A for 12  h. 
The mRNA level of MMP-3 was measured by real-time 
RT-PCR.
c‑Fos, c‑Jun and IκB‑α activation in HS‑SY‑II cells stimulated 
with IL‑17A
HS-SY-II cells were stimulated with IL-17A (10  ng/ml) 
for 0–300 min. Whole-cell lysates were subjected to SDS-
PAGE and western blot analysis, with the blots probed 
for phosphorylated c-Fos, c-Jun, and IκB-α. Following 
visualization, the blots were stripped and re-probed for 
c-Fos, c-Jun and IkB-α. Equivalent protein aliquots of cell 
lysates were also analyzed for β-actin.
Effect of AP‑1 inhibitor on IL‑17A‑induced MMP‑3 
expression in HS‑SY‑II cells
HS-SY-II cells were cultured with inhibitor of AP-1 
(SR11302, 0.1-1  μM; R&D systems) for 1  h, then incu-
bated in the presence or absence of IL-17A (10 ng/ml) for 
12 h. The mRNA level of MMP-3 was measured by real-
time RT-PCR.
Effect of MAPKs inhibitors on IL‑17A‑induced c‑Fos 
and c‑Jun phosphorylation in HS‑SY‑II cells
HS-SY-II cells were pretreated or not with 10 μM U0126, 
10 μM SB239063, and 10 μM SP6000125 for 1 h, followed 
by incubation with 10  ng/ml IL-17A for 3  h. Whole-cell 
lysates were subjected to SDS-PAGE and western blot 
analysis, with the blots probed for phosphorylated c-Fos 
and c-Jun. Following visualization, the blots were stripped 
and re-probed for c-Fos and c-Jun. Equivalent protein ali-
quots of cell lysates were also analyzed for β-actin.
Statistical analysis
All statistical analyses were carried out using statistical 
software EZR (Easy R, Saitama Medical center, Saitama, 
Japan: http://www.jichi.ac.jp/saitama-sct/SaitamaHP.files/
statmed.html), which is based on the R and R commander 
[16]. All data were expressed as the mean  ±  standard 
deviation (SD) obtained from three independent experi-
ments and analyzed by a pairwise t test with a Holm-Bon-
ferroni correction for multiple comparisons. P < 0.01 were 
considered to be statistically significant.
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Results
Effect of IL‑17A‑IL‑17R interaction on MMP‑3 production 
by HS‑SY‑II cells
HS-SY-II cells were incubated in the presence or 
absence of IL-17A. Figure  1a shows the time-depend-
ent enhancement of MMP-3 mRNA by IL-17A. Maxi-
mum enhancement, as determined by real time RT-PCR 
analysis (3.2-fold increase), occurred after 12  h of 
stimulation. Western blotting showed that the expres-
sion of MMP-3 protein was substantially enhanced in 
HS-SY-II cells treated for 18  h with IL-17A (Fig.  1b). 
Immunofluorescence analysis revealed the constitu-
tive cell-surface expression of IL-17R by HS-SY-II cells 
(Fig.  1c). To further examine the role of IL-17R as an 
IL-17A receptor in enhancement of MMP-3, HS-SY-II 
cells were pre-treated with IL-17R neutralizing antibody 
before the addition of IL-17A. The potent induction of 
MMP-3 mRNA induced by IL-17A was blocked by IL-
17R neutralizing antibody in a dose-dependent manner 
(Fig. 1d).
Effect of ERK1/2, p38 MAPK, and JNK on IL‑17A‑induced 
MMP‑3 expression
Treatment with IL-17A enhanced the phosphorylation 
of three components of the MAPKs pathway, ERK1/2 
(P-ERK1/2), p38 MAPK (P-p38) and JNK (P-JNK), after 
15–180 min (Fig. 2a). Thus, we next investigated whether 
the inhibition of any of these proteins affected the IL-
17A-induced expression of MMP-3 in HS-SY-II cells. The 
cells were pre-treated with specific inhibitors of ERK1/2 
(U0126), p38 MAPK (SB239063), and JNK (SP600125), 
and then stimulated with IL-17A. Real time RT-PCR 
revealed that the inhibition of ERK1/2 (Fig.  2b), p38 
MAPK (Fig. 2c), and JNK (Fig. 2d) abolished the ability of 
IL-17A to induce MMP-3 mRNA expression.
Effect of AP‑1 activation on IL‑17A‑induced MMP‑3 
expression
IL-17A stimulation resulted in the phosphorylation of 
c-Fos (P–c-Fos) and c-Jun (P–c-Jun), the major com-
ponents of the AP-1 transcription factor complex, in a 
Fig. 1 Effect of IL-17A on MMP-3 production by HS-SY-II cells. a Representative the mRNA level of MMP-3 in HS-SY-II cells stimulated with IL-17A. 
Data are expressed as the mean ± SD of triplicate cultures. *Indicates statistical significance of p < 0.01. b Western blot for MMP-3 in HS-SY-II cells 
stimulated with IL-17A. c Represents immunofluorescent staining for IL-17R in HS-SY-II cells. Merge image is digital three-color overlay of IL-17R 
(green), rhodamine isothiocynate-phalloidin (red), and DAPI detection of nuclei (blue). The bars indicate 100 μm. d Representative the mRNA level 
of MMP-3 in HS-SY-II cells pretreated with IL-17R Ab, followed by incubation with IL-17A. Data are expressed as the mean ± SD of triplicate cultures. 
*Indicates statistical significance of p < 0.01
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time-dependent manner. Activation occurred within 
180  min (Fig.  3a), whereas IL-17A had no effect on 
NF-κB activation, as evidenced by phosphorylation 
(P-IκB-α) or degradation of IκB-α (Fig. 3b). To determine 
the role of AP-1 activity in IL-17A-induced expression 
of MMP-3, HS-SY-II cells were pre-treated with AP-1 
blocking synthetic peptide (SR11302) prior to their stim-
ulation with IL-17A. Real time RT-PCR revealed that 
SR11302 pre-treatment effectively blocked IL-17A-in-
duced MMP-3 mRNA expression in a dose-dependent 
manner (Fig. 3c).
Effect of ERK1/2, p38 MAPK, and JNK inhibitors on AP‑1 
activation mediated by IL‑17A
Since the activation of MAPKs and AP-1 was neces-
sary for IL-17A-induced MMP-3 expression in HS-SY-II 
cells, we asked whether the phosphorylation of ERK1/2, 
p38 MAPK, and JNK was associated with AP-1 activa-
tion. HS-SY-II cells were pre-treated with the inhibitors 
U0126 (ERK1/2), SB239063 (p38 MAPK), and SP600125 
(JNK) and then stimulated with IL-17A. Western blotting 
revealed that U0126 and SP600125 attenuated the IL-
17A-induced phosphorylation of c-Fos and c-Jun (Fig. 4a, 
Fig. 2 Effects of ERK1/2, p38 MAPK, and JNK on IL-17A-induced MMP-3 expression. a Western blot for components of the MAPKs pathway in 
HS-SY-II cells stimulated with IL-17A. b–d Representative the mRNA level of MMP-3 in HS-SY-II cells pretreated with U0126 (b), SB239063 (c), and 
SP6000125 (d), followed by incubation with IL-17A. Data are expressed as the mean ± SD of triplicate cultures. *Indicates statistical significance of 
p < 0.01
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c) whereas SB239063 suppressed the IL-17A-stimulated 
phosphorylation of c-Fos but not c-Jun (Fig. 4b).
Discussion
Since previous studies have shown that MMP-3 is capa-
ble of stimulating spontaneous tumor development in 
mammary gland and lung [17–19], knowledge of MMP-3 
regulation is of importance for developing therapeutic 
strategies. On the other hand, the link between inflam-
mation and carcinogenesis is well known that extracel-
lular factors, including cytokines and growth factors, 
have been implicated in the regulation in different types 
of tumor cells [20, 21]. Previous study reported that IL-
17A and IL-17R interaction enhanced the metastasis of 
osteosarcoma cells via the expression of VEGF, MMP-9 
and CXCR4 [22]. In the present study, we have explored 
the role of IL-17A in the MMP-3 expression of synovial 
sarcoma cell lines, HS-SY-II.
The results of this study indicated that MMP-3 tran-
scription and protein synthesis are stimulated in HS-SY-
II cells in response to IL-17A. The binding of IL-17A to 
its receptor is thought to mediate the biological effects 
of IL-17A [23]. IL-17R is an ubiquitous transmembrane 
glycoprotein which is expressed by several types of cells 
including tumor cells [24, 25]. In this study, we first 
confirmed the constitutive cell-surface expression of IL-
17R by HS-SY-II cells. We also demonstrated that IL-17R 
neutralizing antibody remarkably inhibited the effect of 
IL-17A on MMP-3 expression. These findings suggest 
that the stimulatory effect of IL-17A on MMP-3 expres-
sion is due to its interaction with IL-17R.
After the binding of IL-17A to its receptor, Act1 asso-
ciates with IL-17R, followed by the activation of down-
stream signaling molecules including MAPKs [26], 
important mediators of a variety of physiopathological 
cellular processes, including cell death, cell survival, pro-
liferation, and migration [27]. In the present study, we 
found that the ERK1/2, p38 MAPK and JNK pathways 
were rapidly and transiently activated in cells treated with 
IL-17A. Moreover, chemical inhibitors of ERK1/2, p38 
MAPK, and JNK down-regulated the IL-17A-induced 
stimulation of MMP-3 mRNA expression. Therefore, we 
speculated that induction of MMP-3 expression in IL-
17A-treated HS-SY-II cells may occur because of activa-
tion of MAPKs.
MMP promoters harbor cis-elements that allow the 
regulation of MMP gene expression by a diverse set of 
trans-activators, including AP-1 [28]. Various stimuli 
lead to the activation of c-Fos and c-Jun products, which 
heterodimerize and bind to AP-1 sites within MMP-3 
Fig. 3 Effect of AP-1 activation on IL-17A-induced MMP-3 expression. a, b Western blot for components of the AP-1 transcription factor complex (a) 
and IκB-α (b) in HS-SY-II cells stimulated with IL-17A. c Representative the mRNA level of MMP-3 in HS-SY-II cells pretreated with SR11302, followed 
by incubation with IL-17A. Data are expressed as the mean ± SD of triplicate cultures. *Indicates statistical significance of p < 0.01
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gene promoters [29]. Previous studies reported that the 
phosphorylation of both c-Fos and c-Jun was involved in 
AP-1 activation [30] and that the translocation of phos-
phorylated c-Jun from the cytoplasm to the nucleus 
activated AP-1 [15, 31]. Western blotting revealed that 
the phosphorylation of c-Fos and c-Jun protein was 
enhanced by IL-17A. The importance of AP-1 activation 
in IL-17A-stimulated MMP-3 expression was demon-
strated clearly by the dramatic decrease in MMP-3 gene 
expression induced by SR11302.
It is also well known that AP-1 transactivation, by 
increasing the abundance of AP-1 components and/or 
altering the phosphorylation of its subunits c-Fos and 
c-Jun, is regulated by the MAPKs pathway [32, 33]. We 
investigated the relationship between MAPKs and AP-1 
in HS-SY-II cells stimulated with IL-17A and found that 
ERK1/2, p38 MAPK, and JNK, all of which are activated 
by IL-17A, were required for IL-17A-induced c-Fos 
phosphorylation. In addition, ERK1/2 and JNK acti-
vation were shown to be involved in IL-17A-induced 
c-Jun phosphorylation. These results provide evidence 
of an important link between MAPKs activation and 
AP-1 in HS-SY-II cells stimulated with IL-17A, and 
strongly support our speculation that MAPKs activation 
Fig. 4 Effects of ERK1/2, p38 MAPK and JNK inhibitors on AP-1 activation mediated by IL-17A. a–c: Western blot for components of the AP-1 tran-
scription factor complex in HS-SY-II cells pretreated with U0126 (a), SB239063 (b), and SP6000125 (c), followed by incubation with IL-17A
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regulates MMP-3 expression. To further determine the 
interaction between MAPKs and AP-1 in HS-SY-II cells, 
silencing of MAPKs expression by siRNA or shRNA will 
be needed.
It has been reported that the chromosomal transloca-
tion t (X; 18) that produces the chimeric gene SYT-SSX at 
high frequency in synovial sarcomas [34–38] and that the 
expression of SYT-SSX is considered to play a central role 
in tumorigenesis [39]. HS-SYII cells genetically possess 
the SS18-SSX1, whereas other human sarcoma cell lines, 
SYO-1 and Fuji cells have another type of chimeric gene 
SS18-SSX2. Further studies are needed to examine the 
effect of IL-17A/IL-17R interaction on viability, migra-
tion and invasion of other human sarcoma cells lines, as 
well as of primary synovial sarcoma tissue.
These findings might provide mechanistic explanation 
for the pathogenesis in synovial sarcoma, and suggested 
that targeting IL-17A/IL-17R pathway was a novel prom-
ising strategy to treat patients with synovial sarcoma.
Conclusion
Our preliminary findings provide a valuable insight how 
IL-17A may contribute to the pathogenesis of synovial 
sarcoma by stimulating MMP-3 expression. We showed 
that the interaction of IL-17A with its receptor, IL-17R, 
stimulates ERK1/2, p38 MAPK, and JNK activation, 
which in turn initiates the activation of AP-1, followed by 
an increase in MMP-3 expression.
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